Paul G. Richardson
Paul Richardson received his medical degree from the Medical College of St. Bartholomew's Hospital, University of London. He was a chief resident at the Royal Marsden Hospital, London, before coming to USA. Dr. Richardson completed a clinical fellowship in hematology and medical oncology at Baystate Medical Center, Tufts University School of Medicine. He was a Vsiting Fellow at Dana Farber in 1993 and then joined it as a Junior Faculty in 1994, spending five years with Cancer Pharmacology and the Solid Tumor Autologous Marrow Program. During this time, he completed a medical residency at Beth Israel Hospital, and then joined the Jerome Lipper Multiple Myeloma Center in 1999, becoming its Clinical Director in 2001. Dr. Richardson has been an author/coauthor of over 128 original articles in peer-reviewed publications including the Journal of Clinical Oncology, Blood, Clinical Cancer Research, and the New England Journal of Medicine, as well as authoring over 80 reviews, editorials, and book chapters. Dr. Richardson is a highly-sought Invited Lecturer, and is leading multiple efforts in combination therapies in relapsed and refractory myeloma—an area of primary interest to him. He has been a leader in the clinical development of bortezomib and lenalidomide for the treatment of myeloma, as well as serving currently as a Principal Investigator and study Chairman for several clinical trials relating to other areas of myeloma treatment.
Biography Updated on 9 April 2008